000			02250cam a2200325 a 4500
003			EG-GiCUC
008			170322s2016 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.08.05.M.Sc.2016.Ra.D
100	0		_aRamy Sayed Aboelella Ahmed
245	1	0	_aDesign and synthesis of thieno[2,3-d]pyrimidine derivatives and their biological evaluation as Antitumor and anti-HIV agents / _cRamy Sayed Aboelella Ahmed ; Supervised Fatma Abdelfattah Ragab , Sahar Mahmoud Abouseri , Diaa Abdelsamei
246	1	5	_aHIVتصميم و تشييد بعض مشتقات الثيينو (3,2-د)بيريميدين و تقييم فاعليتها البيولوجية كمضادات للأورام فيروس
260			_aCairo : _bRamy Sayed Aboelella Ahmed , _c2016
300			_a127 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Pharmaceutical Chemistry
520			_aIn a search for new cytotoxic agents with improved anticancer profile, some new thienopyrimidine and thienotriazolopyrimidine derivatives were synthesized. All the synthesized compounds are tested for their in-vitro cytotoxicity against human breast cancer cell line (MCF-7) in which tyrosine kinases are highly expressed. All target compounds are then subjected for further evaluation against receptor tyrosine kinase enzymes; namely, epidermal growth factor receptor (EGFR), (ErbB-2) and vascular endothelial growth factor receptor-2 (VEGFR-2).Compounds in series I were designed to be nonnucleoside reverse transcriptase inhibitors (NNRTIs). Compounds Va-f were assayed for their inhibitory activity against HIV-1 (IIIB strain) and HIV-2 (ROD strain) using nevirapine as a reference inhibitor. They were found to be moderately active against reverse transcriptase
530			_aIssued also as CD
653		4	_aEGFR
653		4	_aMCF-7
653		4	_aThienotriazolopyrimidine
700	0		_aDiaa Abdelsamei , _eSupervisor
700	0		_aFatma Abdelfattah Ragab , _eSupervisor
700	0		_aSahar Mahmoud Abouseri , _eSupervisor
905			_aEnas _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c60370 _d60370